{"count": 5, "results": [{"_id": "24655729", "pmid": 24655729, "title": "Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.", "journal": "Lancet", "authors": ["Chataway J", "Schuerer N", "Alsanousi A", "Chan D", "MacManus D", "Hunter K", "Anderson V", "Bangham CR", "Clegg S", "Nielsen C", "Fox NC", "Wilkie D", "Nicholas JM", "Calder VL", "Greenwood J", "Frost C", "Nicholas R"], "date": "2014-06-28T00:00:00Z", "doi": "10.1016/S0140-6736(13)62242-4", "meta_date_publication": "2014 Jun 28", "meta_volume": "383", "meta_issue": "9936", "meta_pages": "2213-21", "score": 50049.324, "text_hl": "The mean annualised @<m>DISEASE_Atrophy</m> @DISEASE_MESH:D001284 @@@atrophy@@@ rate was significantly lower in @SPECIES_9606 @@@patients@@@ in the @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ group (0 288% per year [SD 0 521]) than in those in the placebo group (0 584% per year [0 498]). ", "citations": {"NLM": "Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CR, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014 Jun 28;383(9936):2213-21. PMID: 24655729", "BibTeX": "@article{24655729, title={Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.}, author={Chataway J and Schuerer N and Alsanousi A and Chan D and MacManus D and Hunter K and Anderson V and Bangham CR and Clegg S and Nielsen C and Fox NC and Wilkie D and Nicholas JM and Calder VL and Greenwood J and Frost C and Nicholas R}, journal={Lancet}, volume={383}, number={9936}, pages={2213-21}}"}}, {"_id": "22080086", "pmid": 22080086, "title": "Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes.", "journal": "Free Radic Biol Med", "authors": ["Kwak HB", "Thalacker-Mercer A", "Anderson EJ", "Lin CT", "Kane DA", "Lee NS", "Cortright RN", "Bamman MM", "Neufer PD"], "date": "2012-01-01T00:00:00Z", "doi": "10.1016/j.freeradbiomed.2011.10.449", "meta_date_publication": "2012 Jan 1", "meta_volume": "52", "meta_issue": "1", "meta_pages": "198-207", "score": 50047.016, "text_hl": "These data demonstrate that @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ induces myotube @<m>DISEASE_Atrophy</m> @DISEASE_MESH:D001284 @@@atrophy@@@ and cell loss associated with impaired @CHEMICAL_Adenosine_Diphosphate @CHEMICAL_MESH:D000244 @@@ADP@@@-stimulated maximal mitochondrial respiratory capacity, mitochondrial oxidative stress, and apoptosis in primary @SPECIES_9606 @@@human@@@ skeletal myotubes, suggesting that @DISEASE_Mitochondrial_Diseases @DISEASE_MESH:D028361 @@@mitochondrial dysfunction@@@ may underlie @SPECIES_9606 @@@human@@@ statin-induced @DISEASE_Muscular_Diseases @DISEASE_MESH:D009135 @@@myopathy@@@.", "citations": {"NLM": "Kwak HB, Thalacker-Mercer A, Anderson EJ, Lin CT, Kane DA, Lee NS, Cortright RN, Bamman MM, Neufer PD. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med. 2012 Jan 1;52(1):198-207. PMID: 22080086", "BibTeX": "@article{22080086, title={Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes.}, author={Kwak HB and Thalacker-Mercer A and Anderson EJ and Lin CT and Kane DA and Lee NS and Cortright RN and Bamman MM and Neufer PD}, journal={Free Radic Biol Med}, volume={52}, number={1}, pages={198-207}}"}}, {"_id": "25300705", "pmid": 25300705, "title": "Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo.", "journal": "Arch Toxicol", "authors": ["Bonifacio A", "Mullen PJ", "Mityko IS", "Navegantes LC", "Bouitbir J", "Krähenbühl S"], "date": "2016-01-01T00:00:00Z", "doi": "10.1007/s00204-014-1378-4", "meta_date_publication": "2016 Jan", "meta_volume": "90", "meta_issue": "1", "meta_pages": "203-15", "score": 50046.137, "text_hl": "Markers of apoptosis were increased in @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@-treated @CELLLINE_CVCL:0286 @@@H9c2@@@ cells. ", "citations": {"NLM": "Bonifacio A, Mullen PJ, Mityko IS, Navegantes LC, Bouitbir J, Krähenbühl S. Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo. Arch Toxicol. 2016 Jan;90(1):203-15. PMID: 25300705", "BibTeX": "@article{25300705, title={Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo.}, author={Bonifacio A and Mullen PJ and Mityko IS and Navegantes LC and Bouitbir J and Krähenbühl S}, journal={Arch Toxicol}, volume={90}, number={1}, pages={203-15}}"}}, {"_id": "17583829", "pmid": 17583829, "title": "[Cerebrotendinous xanthomatosis].", "journal": "Dtsch Med Wochenschr", "authors": ["Burghaus L", "Liu W", "Haupt WF"], "date": "2007-07-29T00:00:00Z", "doi": "10.1055/s-2007-982053", "meta_date_publication": "2007 Jul 29", "meta_volume": "132", "meta_issue": "27", "meta_pages": "1463-6", "score": 50034.28, "text_hl": "The cerebral computed tomography revealed slight @<m>DISEASE_Atrophy</m> @DISEASE_MESH:D001284 @@@cerebral atrophy@@@, predominantly affecting the cerebellum. ", "citations": {"NLM": "Burghaus L, Liu W, Haupt WF. [Cerebrotendinous xanthomatosis]. Dtsch Med Wochenschr. 2007 Jul 29;132(27):1463-6. PMID: 17583829", "BibTeX": "@article{17583829, title={[Cerebrotendinous xanthomatosis].}, author={Burghaus L and Liu W and Haupt WF}, journal={Dtsch Med Wochenschr}, volume={132}, number={27}, pages={1463-6}}"}}, {"_id": "25887766", "pmid": 25887766, "title": "Progressive multiple sclerosis.", "journal": "Curr Opin Neurol", "authors": ["Ontaneda D", "Fox RJ"], "date": "2015-06-01T00:00:00Z", "doi": "10.1097/WCO.0000000000000195", "meta_date_publication": "2015 Jun", "meta_volume": "28", "meta_issue": "3", "meta_pages": "237-43", "score": 50031.13, "text_hl": "Clinical trial experience to date in @DISEASE_Multiple_Sclerosis_Chronic_Progressive @DISEASE_MESH:D020528 @@@PMS@@@ has been negative with anti-inflammatory medications used in relapsing @DISEASE_Multiple_Sclerosis @DISEASE_MESH:D009103 @@@MS@@@. @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ was recently tested in a phase II trial and showed a 43% reduction of annualized @<m>DISEASE_Atrophy</m> @DISEASE_MESH:D001284 @@@atrophy@@@ progression in secondary progressive @DISEASE_Multiple_Sclerosis @DISEASE_MESH:D009103 @@@MS@@@. ", "citations": {"NLM": "Ontaneda D, Fox RJ. Progressive multiple sclerosis. Curr Opin Neurol. 2015 Jun;28(3):237-43. PMID: 25887766", "BibTeX": "@article{25887766, title={Progressive multiple sclerosis.}, author={Ontaneda D and Fox RJ}, journal={Curr Opin Neurol}, volume={28}, number={3}, pages={237-43}}"}}]}